Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding
Others
Ratios

NewAmsterdam Pharma (NAMSW) Income towards Parent Company (2023 - 2025)

Historic Income towards Parent Company for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2025 value amounting to -$72.0 million.

  • NewAmsterdam Pharma's Income towards Parent Company fell 33254.04% to -$72.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$221.1 million, marking a year-over-year decrease of 1115.4%. This contributed to the annual value of -$241.6 million for FY2024, which is 3654.46% down from last year.
  • NewAmsterdam Pharma's Income towards Parent Company amounted to -$72.0 million in Q3 2025, which was down 33254.04% from -$17.4 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Income towards Parent Company registered a high of -$16.6 million during Q3 2024, and its lowest value of -$93.8 million during Q1 2024.
  • For the 3-year period, NewAmsterdam Pharma's Income towards Parent Company averaged around -$50.9 million, with its median value being -$44.6 million (2023).
  • In the last 5 years, NewAmsterdam Pharma's Income towards Parent Company skyrocketed by 6468.08% in 2024 and then plummeted by 33254.04% in 2025.
  • NewAmsterdam Pharma's Income towards Parent Company (Quarter) stood at -$49.5 million in 2023, then plummeted by 86.34% to -$92.2 million in 2024, then increased by 21.88% to -$72.0 million in 2025.
  • Its Income towards Parent Company stands at -$72.0 million for Q3 2025, versus -$17.4 million for Q2 2025 and -$39.5 million for Q1 2025.